North America HIV Therapeutics Market Analysis Report [2022-30]

North America HIV Therapeutics Market Analysis

$ 3999

The North American HIV therapeutics market is expected to reach $7.81 Bn by 2030, up from $5.02 Bn in 2022, with a CAGR of 5.7% from 2022 to 2030. North American players such as Gilead Sciences, Merck & Co, Johnson & Johnson, and AbCellera Biologics dominate the North American HIV therapeutics market. The North American government policies, health infrastructure, lifestyle, and initiatives by international organizations to manage HIV infections propel the market. The North American HIV therapeutics market is divided into 5 segments type, product, geography, end user, and distribution channel.

ID: IN10NAPH037 CATEGORY: Pharmaceuticals GEOGRAPHY: North America AUTHOR: Vishwa Modhia

Buy Now

North America HIV Therapeutics Market Analysis Summary

The North American HIV therapeutics market is expected to reach $7.81 Bn by 2030, up from $5.02 Bn in 2022, with a CAGR of 5.7% from 2022 to 2030.

According to UNAIDS, there were 1.7 Mn HIV-positive people in North America by 2020. According to the Centers for Disease Control and Prevention (CDC), there were approximately 36,801 new HIV diagnoses in the United States in 2019. According to the Public Health Agency of Canada, there were 2,354 new HIV diagnoses in Canada in 2019. HIV disproportionately affects certain populations in North America, including men who have sex with men, transgender people, injection drug users, and Black and Latinx communities.

Despite the fact that the overall number of new HIV diagnoses in North America has been declining in recent years, disparities in HIV incidence and prevalence remain. HIV treatment and care in North America have greatly improved, and antiretroviral therapy (ART) is widely available. However, challenges remain in ensuring that all HIV-positive people have access to quality care and treatment.

North America HIV Therapeutics Market Analysis

Market Dynamics

Market Growth Drivers Analysis

An increase in the incidence of diagnosis and treatment and a rise in the use of advanced therapies are aiding the growth of the HIV medications market in North America. Another factor aiding the growth of the HIV medicines market in North America is a greater diagnosis and treatment rate, along with a spike in the use of advanced therapies. The North American region now has one of the strongest economies, which has resulted in a well-established healthcare system.; this is one of the main drivers of the HIV medication market's development in the region. Exposure to needles or syringes contaminated with infected body fluids or tissues and lack of awareness regarding transmission risk factors are the two primary factors influencing the market growth. These elements may entice new entrants into the North American HIV therapeutics market.

Market Restraints

HIV medications can be very expensive, which can be a significant barrier to access for people who do not have adequate health insurance coverage or financial resources. Despite advances in HIV treatment and care, stigma and discrimination against HIV-positive people can remain a significant issue in North America. This can cause people to be hesitant to seek care or disclose their HIV status, which can have an impact on the quality of care they receive. While HIV testing and treatment are widely available in North America, some populations, such as injection drug users or those who are incarcerated, may face barriers to care. Furthermore, some people who have been diagnosed with HIV may not be linked to care or may have treatment interruptions. Developing new HIV drugs can be challenging due to the complexity of the virus and the need for large-scale clinical trials to establish safety and efficacy. These factors may discourage new entrants to enter North America's HIV therapeutics market.

Competitive Landscape

Key Players

Gilead Sciences (USA)
ViiV Healthcare (USA)
Merck & Co (USA)
Bristol-Myers Squibb (USA)
AbbVie (USA)
Johnson & Johnson (USA)
Trillium Therapeutics (CAN)
AbCellera Biologics (CAN)
Aptevo Therapeutics (CAN)
Centre for Commercialization of Regenerative Medicine (CAN)

Recent Notable Updates

January 2023: According to the company's most recent Securities and Exchange Commission filing, Kornitzer Capital Management increased its holdings in Gilead Sciences shares by 0.5 % in the third quarter. Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes medicines for unmet medical needs in the United States. The company sells the HIV/AIDS medications Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla.

December 2022: The Health Action Alliance and ViiV Healthcare have officially launched the US Business Action to End HIV, a new coalition of corporations committed to accelerating progress toward ending HIV in the United States by 2030. Ada Health, Avita, BLK, Chispa, CVS Health, Gilead Sciences, Healthvana, National LGBT Chamber of Commerce, OraSure Technologies, The Powell Companies Real, Tinder, Uber, ViiV Healthcare, Walgreens, and Walmart are among the coalition's founding members.

Healthcare Regulations

Various regulatory agencies at the federal and state/provincial levels oversee HIV therapeutics regulation in North America. The Food and Drug Administration (FDA) in the United States is in charge of regulating and approving HIV medications for sale and distribution in the country. The FDA's Center for Drug Evaluation and Research (CDER) reviews and evaluates new drug applications submitted by drug manufacturers for safety and efficacy.

Health Canada is in charge of regulating HIV therapeutics in Canada. It is also in charge of evaluating and approving drugs for sale and distribution in the country. The Therapeutic Products Directorate (TPD) of Health Canada reviews drug submissions and evaluates their safety, efficacy, and quality. Aside from federal agencies, some states in the United States and Canadian provinces have their own regulatory agencies that oversee the distribution and use of HIV medications within their respective jurisdictions. In California, for example, the Office of AIDS (OA) of the Department of Public Health regulates HIV medications and services through its AIDS Drug Assistance Program (ADAP).

Reimbursement Policies

Access to HIV treatment and care in North America has improved significantly in recent years, and reimbursement for HIV therapeutics is generally good, though it can still vary depending on individual insurance plans and coverage policies. Medicaid and the Ryan White Comprehensive AIDS Resources Emergency (CARE) Act in the United States cover HIV treatment, including antiretroviral therapy (ART) and other medications used to manage HIV-related conditions. Furthermore, many private insurance policies cover HIV treatment.

The US President's Emergency Plan for AIDS Relief is led, managed, and overseen by the Office of the US Global AIDS Coordinator and Global Health Diplomacy (PEPFAR). In Canada, the majority of provincial and territorial health insurance plans cover HIV treatment, including ART and other HIV-related medications. Patients may also be eligible for private insurance coverage.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

HIV Therapeutics Segmentation

By Types (Revenue, USD Billion):

Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
Coreceptor Antagonists
Entry and Fusion Inhibitors
Integrase Inhibitors
Protease Inhibitors (PIs)
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.